U.S. FDA Inspection Finds Numerous Concerns At Wockhardt Chikalthana Plant – Report
This article was originally published in PharmAsia News
A U.S. FDA inspection of Wockhardt Ltd.’s Chikalthana plant about 200 miles east of the financial hub of Mumbai came up with numerous concerns about quality control at the factory that produces a generic version of Toprol-XL (metoprolol succinate), according to a report by Bloomberg News.
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.